Animal-Free Recombinant Human IL-13 0 ReviewsSubmit a Review Product Details Catalog Number: AF-200-13 Description: IL-13 is an immunoregulatory cytokine produced primarily by activated Th2 cells, and also by mast cells and NK cells. Targeted deletion of IL-13 in mice resulted in impaired Th2 cell development and indicated an important role for IL-13 in the expulsion of gastrointestinal parasites. IL-13 exerts anti-inflammatory effects on monocytes and macrophages and it inhibits the expression of inflammatory cytokines such as IL-1β, TNF-α, IL-6 and IL-8. IL-13 has also been shown to enhance B cell proliferation and to induce isotype switching, resulting in increased production of IgE. Blocking of IL-13 activity inhibits the pathophysiology of asthma. Human and murine IL-13 are cross-species reactive. Recombinant Human IL-13 is a 12.6 kDa protein consisting of 115 amino acid residues. Manufactured using all Animal-Free reagents. Source: E.coli Synonyms: NC30 (Human), P600 (Murine) AA Sequence: MSPGPVPPST ALRELIEELV NITQNQKAPL CNGSMVWSIN LTAGMYCAAL ESLINVSGCS AIEKTQRMLS GFCPHKVSAG QFSSLHVRDT KIEVAQFVKD LLLHLKKLFR EGRFN Purity: ≥ 98% by SDS-PAGE gel and HPLC analyses. Biological Activity: Determined by its ability to stimulate the proliferation of human TF-1 cells. The expected ED50 is ≤ 1.0 ng/ml, corresponding to a specific activity of ≥1 x 106 units/mg. This product has been tested against the WHO standard. International Unit information can be found here. Calculated Molecular Weight: 12.6 kDa Accession Number: P35225 Gene ID: 3596 Endotoxin: Endotoxin level is < 0.01 ng/ug of protein (< 0.1 EU/ug) Cross Reactivity Cited in References: Human, Mouse References PubMed SDS CoA Search Product Line Country Of Origin: USA Not for human use. Research Interest COVID-19 AIDS/HIV Cancer Immune System Inflammation Stem Cells & Differentiation Allergy Recent Citations First Author Wang, S Title USP24 promotes drug resistance during cancer therapy Citation Cell Death and Differentiation; 28(9) pg2690-2707 PubMed ID 33846536 First Author Buzza, M S Title Inflammatory cytokines down-regulate the barrier-protective prostasin-matriptase proteolytic cascade early in experimental colitis. Citation The Journal of Biological Chemistry; 292(26) pg10801-10812 PubMed ID 28490634 First Author Alevy, Y G Title IL-13-induced airway mucus production is attenuated by MAPK13 inhibition. Citation The Journal of Clinical Investigation; 122(12) pg4555-68 PubMed ID 23187130
